Table 6 TCM syndrome score analysis
SZF | SZF | Irbesartan | Irbesartan | ||||
|---|---|---|---|---|---|---|---|
Week 0 | Week 24 | p Value | Week 0 | Week 24 | p Value | ||
n = xx | n = xx | n = xx | n = xx | ||||
Evaluation of TCM syndrome | Physical and mental fatigue | xx (xx) | xx (xx) | .xx | xx (xx) | xx (xx) | .xx |
Dry mouth and throat | xx (xx) | xx (xx) | .xx | xx (xx) | xx (xx) | .xx | |
Weakness and soreness of the lower back and knees | xx (xx) | xx (xx) | .xx | xx (xx) | xx (xx) | .xx | |
Qi deficiency and listlessness | xx (xx) | xx (xx) | .xx | xx (xx) | xx (xx) | .xx | |
Spontaneous perspiration | xx (xx) | xx (xx) | .xx | xx (xx) | xx (xx) | .xx | |
Night sweat | xx (xx) | xx (xx) | .xx | xx (xx) | xx (xx) | .xx | |
Dysphoria in chest, palms, and soles | xx (xx) | xx (xx) | .xx | xx (xx) | xx (xx) | .xx | |
Dark purplish lips | xx (xx) | xx (xx) | .xx | xx (xx) | xx (xx) | .xx | |
Edema | xx (xx) | xx (xx) | .xx | xx (xx) | xx (xx) | .xx | |
Efficacy index | Clinical control | xx (xx%) | xx (xx%) | .xx | xx (xx%) | xx (xx%) | .xx |
Obvious therapeutic effect | xx (xx%) | xx (xx%) | .xx | xx (xx%) | xx (xx%) | .xx | |
With therapeutic effect | xx (xx%) | xx (xx%) | .xx | xx (xx%) | xx (xx%) | .xx | |
Invalid | xx (xx%) | xx (xx%) | .xx | xx (xx%) | xx (xx%) | .xx | |
Overall clinical efficiency | xx (xx%) | xx (xx%) | .xx | xx (xx%) | xx (xx%) | .xx | |